About NewLimit

NewLimit is a biotechnology company working to radically extend human healthspan. We are developing medicines to treat age-related diseases by reprogramming the epigenome—a novel therapeutic mechanism designed to restore regenerative potential in aged and diseased cells. By leveraging functional genomics, pooled perturbation screening, and machine learning, we unravel the biology of epigenetic aging through experiments of unprecedented scale.